IRLAB Therapeutics AB
STO:IRLAB A
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.9
19.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one IRLAB A stock under the Base Case scenario is 16.17 SEK. Compared to the current market price of 12.6 SEK, IRLAB Therapeutics AB is Undervalued by 22%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
IRLAB Therapeutics AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for IRLAB A cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
IRLAB Therapeutics AB
Balance Sheet Decomposition
IRLAB Therapeutics AB
Current Assets | 163.4m |
Cash & Short-Term Investments | 98.3m |
Receivables | 65.1m |
Non-Current Assets | 51.2m |
PP&E | 4.4m |
Intangibles | 46.9m |
Other Non-Current Assets | -1k |
Current Liabilities | 142.3m |
Other Current Liabilities | 142.3m |
Non-Current Liabilities | 2.6m |
Long-Term Debt | 2.6m |
Earnings Waterfall
IRLAB Therapeutics AB
Revenue
|
41.6m
SEK
|
Cost of Revenue
|
-115.5m
SEK
|
Gross Profit
|
-73.9m
SEK
|
Operating Expenses
|
-45.2m
SEK
|
Operating Income
|
-119.1m
SEK
|
Other Expenses
|
-330k
SEK
|
Net Income
|
-119.5m
SEK
|
Free Cash Flow Analysis
IRLAB Therapeutics AB
SEK | |
Free Cash Flow | SEK |
IRLAB A Profitability Score
Profitability Due Diligence
IRLAB Therapeutics AB's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
IRLAB Therapeutics AB's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
IRLAB A Solvency Score
Solvency Due Diligence
IRLAB Therapeutics AB's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
IRLAB Therapeutics AB's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IRLAB A Price Targets Summary
IRLAB Therapeutics AB
Dividends
Current shareholder yield for IRLAB A is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
IRLAB A Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Contact
IPO
Employees
Officers
The intrinsic value of one IRLAB A stock under the Base Case scenario is 16.17 SEK.
Compared to the current market price of 12.6 SEK, IRLAB Therapeutics AB is Undervalued by 22%.